All In Biotech

Drug Trial Radar · NCT01384435

A Phase II Double Blind Comparative Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

A Randomized, Double Blind, Placebo-controlled Phase II Study of KPS-0373 in Patients With SCD

Last checked: Nov 19, 2026Latest source record: Dec 3, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

200

Planned (sponsor's estimate)

Start

Not stated

Primary completion

Not stated

Sponsor

Sponsor type
Industry
First posted
Jun 29, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of KPS-0373 compared to placebo in patients with Spinocerebellar Degeneration (SCD).

Conditions

  • SCD

Interventions

  • KPS-0373Drug

  • KPS-0373Drug

  • KPS-0373Drug

  • KPS-0373Drug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in Scale for the assessment and rating of ataxia (SARA)Time frame: 24 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Japan

    Tokyo and Other Japanese City, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.